

# Company Factsheet

May 2026

**hikma.**

## Company description

Hikma is a multinational pharmaceutical company. Listed on the London Stock Exchange, we are a global company with a local presence across North America, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products.

## Acting responsibly

At Hikma, we strive to put better health within reach, every day and make a difference to people's lives.

We have a duty to act responsibly: for our people, patients, communities and the planet. We have identified four focus areas where we can drive positive impact.



## Strategy

We aim to deliver consistent and profitable growth by putting better health within reach every day, creating high-quality medicines and making them accessible for patients around the world. We do this by focusing on three strategic pillars: Strive for excellence, Diversify and differentiate and People and responsibility.



### Injectables

We supply hospitals across our markets with generic and specialty injectable products supported by our manufacturing facilities in the US, Europe and MENA.



### Branded

We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.



### Hikma Rx

We supply oral, respiratory and other generic and specialty products to the North American retail market, leveraging our state-of-the-art manufacturing facility in Columbus, Ohio.

## Key group financials

(Year end December 2025)

**Core revenue**  
2025: \$3,349m  
2024: \$3,156m

**Core operating profit**  
2025: \$741m  
2024: \$719m

**Core EBITDA**  
2025: \$853m  
2024: \$824m


**Core basic EPS**  
2025: 228c  
2024: 224c

**DPS**  
2025: 84c  
2024: 80c


**Net debt to EBITDA**  
2025: 1.6x  
2024: 1.4x

Core results show the underlying performance of the Group, excluding exceptional items.

## % Group core revenue



## Company strengths - Group core revenue by business segment



**Unique and diversified business model**



Injectables **42.5%**  
Branded **25.4%**  
Hikma Rx **31.0%**  
Others 1.2%



**Strong market position**

**#3** generic injectable manufacturer in the US<sup>1</sup>  
**#1** pharmaceutical company in MENA<sup>2</sup>



**Commitment to quality**

**13** US FDA inspected plants  
**12** EMA-inspected plants



**R&D portfolio and pipeline**

**825+** Products  
**300+** Products in our pipeline  
**84** new product launches globally  
Received **99** approvals  
Submitted **139** regulatory fillings



**16%**  
**ROIC**

**Return on average invested capital**  
(Return on average invested capital is calculated as core operating profit after tax divided by the average invested capital (calculated as the average of the opening and closing total equity plus net debt).)

1. IQVIA MAT November 2024, generic injectable volumes by eachees, excluding branded generics and Becton Dickinson

2. Based on internal analysis using data from the following source: IQVIA MIDAS<sup>®</sup> Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: MAT December 2025, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

## Injectables



### Core revenue



### Core operating profit



### Key focus areas

- Continue to grow our base business through our scale and strength of customer relationships
- Launched 50 products globally, including 26 in the US
- Europe and ROW grew by 23%; MENA by 9% and North America by 5%

**Products:** Includes anti-infectives, pain management, cardiovascular, oncology

**Customers:** Includes hospitals, Group Purchasing Organisations, Civica Rx

**Capabilities:** Includes sterile liquid, powder, lyophilised and cytotoxic products, in a broad range of forms, including vials, ampules, bags and prefilled syringes, manufactured in facilities in the US, Portugal, Germany, Italy and MENA


## Branded



### Core revenue



### Core operating profit



### Key focus areas

- We operate in 17 markets across the MENA region
- R&D is focused on key markets and high value therapeutic areas, with an increasing focus on chronic illnesses
- We signed 14 deals in MENA in 2025. Partnerships are a key contributor to this business and we work hard to maintain our partner of choice status with global innovative pharma companies
- Launched 30 products

**Products:** Broad portfolio of branded generics and in-licensed products – we are the partner of choice in the region

**Customers:** Pharmacies and hospitals across the region

**Capabilities:** Manufacturing facilities in seven countries, many of which are both locally approved, and US FDA and EMA-approved. 2,000 sales representatives and support staff across our 17 markets

## Hikma Rx



### Core revenue



### Core operating profit



### Key focus areas

- Differentiation – offer broad portfolio of differentiated products, including nasal sprays and respiratory
- Quality and operational efficiencies – world-class FDA-inspected facilities
- Pipeline – focus on adding complex and specialty products through R&D and partnerships

**Products:** Broad product portfolio encompassing oral solids and liquids and leader in US prescription nasal sprays

**Customers:** 90% of retail generics bought by three customer consortia

**Capabilities:** State of the art facility in Columbus Ohio

### Company information

Chief Executive Officer:  
Executive Vice Chairman and Deputy CEO, MENA:  
Deputy CEO, North America and Europe:  
President, US and Chief R&D Officer:

Said Darwazah  
Mazen Darwazah  
Khalid Nablisi  
Hafrun Fridriksdottir

Hikma Pharmaceuticals PLC  
10 Portman Square  
London W1H 6AZ

### Contacts

See [www.hikma.com](http://www.hikma.com) for contact forms